Democratic presidential candidate Hillary Clinton defended her paid speeches to Wall Street, saying in an interview that aired on Friday that they would not soften her campaign pledges for tougher regulation.
The former U.S. Senator from New York and secretary of state is under pressure from rival candidate Bernie Sanders, who has made her Wall Street ties a top campaign issue and called for her to release transcripts of her remarks. Clinton was reportedly paid millions in appearance fees after leaving the State Department.
Asked whether she could assure U.S. voters that the speeches would not undermine her calls to rein in the financial industry, Clinton told MSNBC: “Absolutely.”
“I’m on the public record. I told them what I’m going to do. I said I’m going to go after big banks that pose a systemic risk. I want you to hold me accountable for that because I will do that exactly,” she told the network’s “Morning Joe” program.
The New York Times, in an editorial late on Thursday, urged Clinton to release the transcripts, saying “voters have every right to know what Mrs. Clinton told these groups.” According to the paper, Clinton earned $11 million in 2014 and the first quarter of 2015 from 51 speeches to banks and other groups and industries.
Clinton has said she will release copies of her remarks when other presidential candidates do the same.
On Friday, she said President Barack Obama’s fundraising from Wall Street had not prevented him from enacting Dodd-Frank financial services reforms after the 2007-2009 financial crisis.
Clinton reiterated her position that regulations must go farther, saying, “Dodd-Frank is great. It gives us a foundation. It doesn’t go far enough. We need to look at these other entities that pose systemic risks, as well.”
As far as so-called unwinding of banks that pose a risk, she added: “We’re going to do in an orderly way so there will not be any surprises.”
Sanders, a U.S. senator from Vermont, is vying with Clinton for the Democratic nomination in the November presidential election.
“I do not receive many millions of dollars from Wall Street or the pharmaceutical industry or other powerful, wealthy interests in this country, and have not given speeches for hundreds of thousands of dollars to Wall Street,” Sanders told a Chicago rally on Thursday, the Washington Post reported.
The next Democratic nominating contest is on Saturday in South Carolina.
(Reporting by Susan Heavey; Editing by Frances Kerry)
What is China doing to stop Beijing’s new coronavirus outbreak?
Over 1,000 flights have been cancelled, schools shut and residents urged not to leave Beijing, as Chinese authorities race to contain a fresh outbreak linked to the capital's largest wholesale food market.
The number of confirmed cases in the capital has shot up to 137 within the last week after two months of no cases, and four other provinces have revealed cases linked to the Beijing cluster.
How did the outbreak begin, and what measures are Beijing taking to contain it?
- What is the origin of the cluster? -
Beijing had turned into a virtual fortress at the height of the pandemic, with people arriving from other regions or countries required to undergo quarantines.
Democrats and Never-Trumpers gaming out ‘doomsday scenarios’ if president refuses to leave office: report
According to a report in the New York Times, Democratic strategists and Never-Trumper conservatives fear Donald Trump will refuse to leave office should he lose in November and are making plans and figuring out their legal options should such an unprecedented state of affairs come to pass.
The report, by the Times' Reid Epstein, begins with one such possible scenario.
‘Retaliation plain and simple’: Vaccine agency top Doc fired by Trump administration files whistleblower complaint
Dr. Rick Bright has retained an attorney and will be filing a whistleblower complaint after the Trump administration fired him from his position as head of the federal agency charged with developing a COVID-19 vaccine. Dr. Bright was moved to a different agency with a narrower focus after he raised concerns over President Donald Trump's obsession with promoting hydroxychloroquine, a malaria drug recent studies found doubles the death rate in coronavirus patients.